The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of diffuse midline glioma harboring an ...

The FDA has approved Ajovy (fremanezumab) for the prevention of episodic migraine in pediatric patients aged 6 to 17 years weighing at least 45kg.

Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.